Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions... Show more
Fortrea Holdings is a global contract research organization (CRO) that runs Phase I–IV clinical trials, clinical pharmacology, and consulting services for pharmaceutical, biotech, and medical-device companies. Spun off from Labcorp in 2023, the company operates as a pure-play clinical development specialist, competing against larger, diversified CRO peers. Its scale — roughly 19,000 employees across about 100 countries and more than 20 therapeutic areas — gives it a broad investigator-site network and a foothold in high-growth areas such as oncology, cardiovascular, and RNA-based therapies.
Fortrea's medium-term positioning hinges on three structural pillars. First, it is narrowing its focus to higher-margin full-service work while remaining selective in FSP contracts that have compressed profitability. Second, the rollout of the FIT platform aims to automate workflows and improve trial predictability, a potential differentiator as sponsors increasingly reward speed and data quality. Third, its growing China pipeline and diversified biotech client base provide incremental demand channels. The primary structural risk is that its revenue base has contracted in recent years, leaving margin execution — not top-line growth — as the near-term driver of investor sentiment.
The most immediate catalyst is Fortrea's next quarterly earnings report, expected around October 29, 2026, which will test whether the company's improving book-to-bill trajectory and margin discipline are translating into sustainable results. Management's full-year 2026 guidance calls for revenue of roughly $2.55 billion to $2.65 billion and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $190 million to $220 million, a range it has already begun to refine upward through the year.
Beyond earnings, analyst rating momentum is a notable sentiment driver. Deutsche Bank upgraded Fortrea to Buy with a $25 price target in October 2026, citing a "fundamental inflection point," while Barclays moved to Overweight at $23. Evercore ISI and Baird also hold Outperform ratings with targets near $25 and $23, respectively. In contrast, Bank of America has maintained a more cautious Underperform stance with a $16 target, and UBS initiated coverage at Neutral ($22), reflecting low visibility into the timing of a revenue rebound. The consensus recommendation across roughly 13 analysts is "Buy," with an average one-year price target near $21.50 — a sign that expectations have become more constructive, though the range of views remains wide.
Fortrea's trajectory is tightly linked to the biopharmaceutical funding cycle. When interest rates are high and capital is scarce, emerging biotech companies delay or cancel trials, directly reducing CRO order flow. Management has noted that biotech funding rebounded meaningfully in late 2025 and into 2026, improving request-for-proposal (RFP) activity and client engagement. A sustained easing in financing conditions would support this recovery, while renewed tightening could stall it.
Large-pharma pipeline budgets, which had been under pressure from reprioritization, have largely stabilized, according to management. Regulatory climate and technology adoption also matter: the shift toward decentralized and AI-enabled trials favors CROs that can deliver efficiency gains. Currency movements add a secondary layer of sensitivity, as Fortrea's guidance assumes foreign-exchange rates hold steady. Net-net, the company's fortunes are leveraged to a cyclical, rate-sensitive demand recovery over which it has limited control.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. The tool is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. It includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking the evolving FTRE story, the engine offers an additional, data-driven lens for monitoring near-term directional signals.
Looking into 2026 and beyond, Fortrea's investment case centers on whether it can convert a stabilizing demand environment into durable, profitable growth. Management is positioning 2026 as a transition year in which cost savings and operational discipline protect margins while biotech and large-pharma demand gradually normalizes. Consensus estimates imply a modest revenue rebound into 2027, with earnings-per-share growth expected to accelerate as efficiency initiatives scale.
Longer term, the structural shift toward outsourced clinical research and the rising complexity of novel therapeutics — including biologics and gene therapies — support secular demand for CRO services. Fortrea's FIT platform and AI-enabled workflows could become meaningful margin levers if adoption progresses as management projects, though benefits are expected to accrue gradually over several years. The principal competitive threats are share losses to larger, better-capitalized peers and continued pressure in the lower-margin FSP segment. Capital allocation priorities — including debt reduction and measured reinvestment — will also shape how much of any recovery flows to shareholders. As with any forward-looking analysis, external analyst price targets are expressions of third-party expectations, not guarantees of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GJH | 9.47 | N/A | N/A |
| Synthetic Fixed-Income Sec STRATS 2004-06 | |||
| BOXA | 103.57 | N/A | N/A |
| Alpha Architect Aggregate Bond ETF | |||
| VFVA | 151.31 | -2.59 | -1.68% |
| Vanguard U.S. Value Factor ETF (VFVA) | |||
| GOOW | 41.33 | -1.35 | -3.16% |
| Roundhill GOOGL WeeklyPay ETF | |||
| DFEN | 39.70 | -3.90 | -8.94% |
| Direxion Daily Aerospace & Defense Bull 3X ETF (DFEN) | |||
A.I.dvisor indicates that over the last year, FTRE has been loosely correlated with RXRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if FTRE jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To FTRE | 1D Price Change % | ||
|---|---|---|---|---|
| FTRE | 100% | -7.94% | ||
| RXRX - FTRE | 37% Loosely correlated | -9.93% | ||
| MRVI - FTRE | 37% Loosely correlated | -2.92% | ||
| TWST - FTRE | 37% Loosely correlated | -7.44% | ||
| ABSI - FTRE | 36% Loosely correlated | -7.97% | ||
| CRSP - FTRE | 36% Loosely correlated | +0.44% | ||
More | ||||
Industry Biotechnology
The 10-day RSI Oscillator for FTRE moved out of overbought territory on October 29, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 18 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 86%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTRE as a result. In 46 of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for FTRE turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In 25 of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
FTRE moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FTRE crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTRE advanced for three days, in 156 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
FTRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 105 of 120 cases where FTRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.984) is normal, around the industry mean (3.596). P/E Ratio (-26.458) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.344) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. FTRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.